Short answer: As of March 2026, there is NO recall of Ozempic, Wegovy, Mounjaro, Zepbound, or other GLP-1 drugs. However, there IS active litigation (MDL 3163) over NAION vision loss, and lawsuits are proceeding without a recall.

No Recall — But Lawsuits Are Active

A product recall and a product liability lawsuit are two very different things. A recall involves a manufacturer or the FDA voluntarily or mandatorily removing a product from the market. A lawsuit allows injured individuals to seek compensation for harm caused by a product — regardless of whether a recall exists.

Most major pharmaceutical mass torts — including Vioxx, Risperdal, roundup, and many others — proceeded through litigation without a prior recall. The GLP-1 vision loss litigation is following the same pattern.

What Is the Current Status of GLP-1 Safety Warnings?

Here is the factual status of safety actions related to GLP-1 drugs and NAION as of March 2026:

Novo Nordisk (Ozempic, Wegovy, Rybelsus):

US labels have NOT been updated to include NAION as an adverse event. This is despite the Harvard study's publication in July 2024 and calls from the ophthalmology community for label updates.

Eli Lilly (Mounjaro, Zepbound, Trulicity):

US labels have not been specifically updated for NAION risk related to tirzepatide. Investigation is ongoing.

FDA:

No recall order issued. The FDA has received adverse event reports of NAION in GLP-1 users. The FDA may issue safety communications or label update requirements as the science develops.

MDL 3163:

The federal GLP-1 NAION MDL was formed in March 2026 in the Eastern District of Pennsylvania. Litigation is active and attorneys are accepting cases.

Why a Recall May Not Come

Several factors make a full recall unlikely in the near term:

  • Benefit-risk calculation: GLP-1 drugs provide substantial benefits for diabetes management and weight loss. The FDA typically doesn't recall drugs unless the risk clearly outweighs the benefit for ALL users
  • Manufacturer incentive: Ozempic, Wegovy, and Mounjaro generate tens of billions of dollars in annual revenue — manufacturers have strong incentive to resist recalls
  • Label update alternative: Rather than recall, the more likely outcome is a "Dear Healthcare Provider" letter or label update adding NAION to the warnings section — similar to how other drugs have added warnings without recalls
  • Absolute risk: While the Harvard study found a significantly elevated relative risk, the absolute incidence of NAION remains relatively low in the overall population

You Don't Need a Recall to File a Lawsuit

This is a critical point many people misunderstand. Product liability lawsuits can proceed — and often succeed — without any FDA recall action. The legal basis is failure to warn: manufacturers had a duty to disclose known risks in their labeling, and failing to do so makes them potentially liable for resulting injuries.

Historically:

  • Vioxx lawsuits were filed and settled for $4.85 billion before/after a voluntary recall
  • Roundup (glyphosate) cases resulted in billions in settlements with no recall
  • Talcum powder lawsuits totaled billions without a formal recall for years
  • Essure, 3M earplugs, and hundreds of other cases proceeded without recalls

What Should You Do Now?

If you took a GLP-1 drug and experienced vision loss:

  1. See an ophthalmologist immediately if you haven't — a documented diagnosis is essential for any claim
  2. Don't wait for a recall — statutes of limitations are running regardless
  3. Gather your records — pharmacy records and eye exam records
  4. Consult an attorney — free case evaluations are available now
Check If You Qualify →